Comparison of four antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in non-small cell lung cancer

摘要: Agents acting on signalling molecules of growth pathways have emerged as therapeutics for non-small cell lung cancer (NSCLC). Among them are inhibitors the epidermal factor receptor (EGFR). To meet Belgian reimbursement criteria erlotinib, patients must an EGFR-positive tumour, defined at least 10% cells showing membranous staining immunohistochemistry. This study compares results obtained with Dako pharmDx kit versus other anti-EGFR antibodies in 634 NSCLC. More than 80% qualify erlotinib therapy using or from Zymed Novocastra; when NeoMarkers used, less 70% will do. Although immunohistochemical stainings EGFR can be performed biopsies, surgical and cytological samples primary metastatic NSCLC, highest positivity rates were biopsies tumours. In conclusion, immunohistochemistry patient selection needs standardization order to avoid influenced by technical issues.